Betnovate

Betnovate

betamethasone

Manufacturer:

GlaxoSmithKline

Distributor:

Zuellig Pharma
Concise Prescribing Info
Contents
Betamethasone-17-valerate
Indications/Uses
Relief of inflammatory & pruritic manifestations of steroid-responsive dermatoses eg, atopic, nummular, seborrhoeic, irritant or allergic contact dermatitis; prurigo nodularis, psoriasis, lichen simplex chronicus & planus, discoid lupus erythematosus, insect bite reactions, miliara. Adjunct to systemic steroid therapy in generalised erythroderma.
Dosage/Direction for Use
Adult, elderly & childn >1 yr Apply thinly to affected area once or bd for up to 4 wk. Patient who frequently relapse Reduce to once daily twice wkly.
Contraindications
Untreated cutaneous infection, rosacea, acne vulgaris, pruritus w/o inflammation, perioral dermatitis, perianal & genital pruritus. Dermatoses in infants <1 yr including dermatitis.
Special Precautions
Hypersensitivity to corticosteroids. Cushing's syndrome & reversible hypothalamic-pituitary-adrenal axis suppression. Increased risk of systemic effects. Concomitant infection. Psoriasis, chronic leg ulcers; visual disturbances. Use w/ occlusive dressings. Prolonged use. Avoid contact w/ face & eyes. Avoid abrupt w/drawal. Renal or hepatic impairment. Pregnancy & lactation. Avoid long-term continuous therapy in infants & childn <12 yr. Elderly.
Adverse Reactions
Pruritus, local skin burning/skin pain.
Drug Interactions
Inhibited metabolism by CYP3A4 inhibitors eg, ritonavir, itraconazole.
ATC Classification
D07AC01 - betamethasone ; Belongs to the class of potent (group III) corticosteroids. Used in the treatment of dermatological diseases.
Presentation/Packing
Form
Betnovate cream 0.1%
Packing/Price
100 g x 1's;15 g x 1's (RM19.05/tube)
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in